Functional imaging of HER2-positive metastatic breast cancer using 64Cu DOTA-trastuzumab positron emission tomography (PET)

被引：0
|
作者：
Mortimer, Joanne E.
Conti, Peter
Tong, Shan
Reyes, Jose
Carroll, Mary I.
Poku, Kofi
Colcher, David
Raubitschek, Andrew Antony
Bading, James R.
Miles, Joshua
机构：
[1] City Hope Canc Ctr, Beckman Res Inst, Duarte, CA USA
[2] USC, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
639
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Correlation of 64Cu-DOTA-trastuzumab positron emission tomography (PET) imaging with HER2 status by immunohistochemistry (IHC).
    Mortimer, Joanne E.
    Park, Jinha Mark
    Carroll, Mary I.
    Poku, Kofi
    Miles, Joshua
    Colcher, David
    Raubitschek, Andrew Antony
    Tri Tran
    Bading, James R.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [12] 64Cu radiolabeled nanomaterials for positron emission tomography(PET) imaging
    Xueqian Chen
    Wenchao Niu
    Zhongying Du
    Yong Zhang
    Dongdong Su
    Xueyun Gao
    Chinese Chemical Letters, 2022, 33 (07) : 3349 - 3360
  • [13] 64Cu radiolabeled nanomaterials for positron emission tomography (PET) imaging
    Chen, Xueqian
    Niu, Wenchao
    Du, Zhongying
    Zhang, Yong
    Su, Dongdong
    Gao, Xueyun
    CHINESE CHEMICAL LETTERS, 2022, 33 (07) : 3349 - 3360
  • [14] Functional Imaging of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Using 64Cu-DOTA-Trastuzumab PET
    Mortimer, Joanne E.
    Bading, James R.
    Colcher, David M.
    Conti, Peter S.
    Frankel, Paul H.
    Carroll, Mary I.
    Tong, Shan
    Poku, Erasmus
    Miles, Joshua K.
    Shively, John E.
    Raubitschek, Andrew A.
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55 (01) : 23 - 29
  • [15] 64Cu-DOTA-trastuzumab PET/CT to predict response to ado-trastuzumab emtansine (TDM1) in HER2-positive metastatic breast cancer.
    Mortimer, Joanne E.
    Bading, James R.
    Frankel, Paul Henry
    Gidwaney, Rita
    Park, John
    Tumyan, Lusine
    Parayno, Maria
    Poku, Kofi
    Colcher, David
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [16] Use of 64Cu-DOTA trastuzumab positron emission tomography to predict pathologic complete response in locally advanced HER2 positive breast cancer
    Mortimer, Joanne
    Rockne, Russell
    Liu, Jessica
    Yuan, Yuan
    Stewart, Daphne
    Waisman, James
    Frankel, Paul
    Kruper, Laura
    Adhikarla, Vikram
    CANCER RESEARCH, 2022, 82 (04)
  • [17] 64Cu-DOTA-trastuzumab PET imaging for HER2-specific primary lesions of breast cancer
    Sasada, S.
    Kurihara, H.
    Kinoshita, T.
    Yoshida, M.
    Honda, N.
    Shimoi, T.
    Shimomura, A.
    Yunokawa, M.
    Yonemori, K.
    Shimizu, C.
    Hamada, A.
    Kanayama, Y.
    Watanabe, Y.
    Fujiwara, Y.
    Tamura, K.
    ANNALS OF ONCOLOGY, 2017, 28 (08) : 2028 - 2029
  • [18] Trastuzumab emtansine in HER2-positive metastatic breast cancer
    Montemurro, Filippo
    LANCET ONCOLOGY, 2017, 18 (06): : 696 - 697
  • [19] Imaging HER-2 positive breast cancer xenografts with positron emission tomography (PET) and Cu-64 labelled bifunctional chelates.
    Yapp, Donald
    Ferreira, Cara
    Crisp, Sarah
    Sutherland, Brent
    Gleave, Martin
    Bensimon, Corrine
    Jurek, Paul
    Kiefer, Gary
    CANCER RESEARCH, 2009, 69
  • [20] Trastuzumab therapy in HER2-positive, metastatic breast cancer
    Smith, A. D.
    Guilbert, K.
    Lister, D.
    Streilein, S.
    Bourrier, V. C.
    Lozar, B.
    Navaratnam, S.
    Harding, G. A.
    Pitz, M. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345